$GNPX
Genprex Reports Exclusive Global Patent, Technology License Deal For Combo Of Its TUSC2 Gene Therapy With Immunotherapies
https://t.co/aCfO23iJYQ

#daytrade #daytrading #stocks #stockmarketnews #stockstowatch